Carol DePriest - Concepedia

Author

Carol DePriest

Hoag Memorial Hospital Presbyterian

Also Known As

C DePriest, C. DePRIEST, C. DePriest, C. Depriest, Carol B. DePriest, Carol DePriest, Carol Depriest

Publications

944

Citations

H-Index

Concepts

All Affiliations

Hoag Memorial Hospital Presbyterian Bloomington Health Foundation Campbell Clinic Minnesota Oncology

About

Carol DePriest is an author at Hoag Memorial Hospital Presbyterian specializing in immunology, immunotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	244
2	Immunology	9	9	244
3	Pathology	4	4	117
4	Cell Biology	1	1	58
5	Surgical Oncology	1	1	23

Carol DePriest

Publications

887

Citations

H-Index

Page 1

	Year	Citations
Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma Robert O. Dillman, Christopher Duma, Patric M. Schiltz, Journal of Immunotherapy	2004	117
Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy Robert O. Dillman, Andrew N. Cornforth, Carol DePriest, Journal of Immunotherapy	2012	74
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Journal for ImmunoTherapy of Cancer	2018	71
Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, Cancer Biotherapy and Radiopharmaceuticals	2009	67
Interferon-Gamma or Granulocyte-Macrophage Colony-Stimulating Factor Administered as Adjuvants With a Vaccine of Irradiated Autologous Tumor Cells From Short-Term Cell Line Cultures: A Randomized Phase 2 Trial of the Cancer Biotherapy Research Group Robert O. Dillman, Michael C. Wiemann, Shankar K. Nayak, Journal of Immunotherapy Short-term Cell LineImmunologyImmunoeditingPathologyImmunotherapy	2003	58
Irradiated Cells from Autologous Tumor Cell Lines as Patient-Specific Vaccine Therapy in 125 Patients with Metastatic Cancer: Induction of Delayed-Type Hypersensitivity to Autologous Tumor is Associated with Improved Survival Robert O. Dillman, Linda D. Beutel, Neil M. Barth, Cancer Biotherapy and Radiopharmaceuticals	2002	46
Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, Cancer Biotherapy and Radiopharmaceuticals	2004	41
Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas Robert O. Dillman, Neil M. Barth, Senthamil R. Selvan, Cancer Biotherapy and Radiopharmaceuticals	2004	37
Patient-Specific Vaccines Derived from Autologous Tumor Cell Lines as Active Specific Immunotherapy: Results of Exploratory Phase I/II Trials in Patients with Metastatic Melanoma Robert O. Dillman, Carol DePriest, Cristina DeLeon, Cancer Biotherapy and Radiopharmaceuticals Tumor Response RateImmunologyImmunoeditingImmune Cell TherapyImmunotherapy	2007	35
Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas Robert O. Dillman, Neil M. Barth, Senthamil R. Selvan, Cancer Biotherapy and Radiopharmaceuticals VaccinationTumor ImmunologyImmunologyTherapeutic VaccineMetastatic Sarcomas	2004	34

Page 1